Myotonic Dystrophy 1

Rare Disease·MeSH: Myotonic Dystrophy

Prevalence

5.0 / 100K

8 drugs in development·2 companies·9 clinical trials

Drug Pipeline by Phase

Phase 2(2)

Drug	Company
pgn-edodm1	PepGen Inc. (PEPG)
pgn-edodm1 for infusion	PepGen Inc. (PEPG)

Phase 1(4)

Drug	Company
ARO-DM1	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
aro-dm1 intravenous infusion	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
aro-dm1 subcutaneous	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Peripheral Blood Stem Cell Infusion	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Phase 4(2)

Drug	Company
Lidocaine Infusion	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Nefopam 120mg/day infusion	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

BioSniper tracks 8 drugs in development for Myotonic Dystrophy 1 across 2 companies.

There are 9 clinical trials targeting Myotonic Dystrophy 1 tracked by BioSniper.

The estimated prevalence of Myotonic Dystrophy 1 is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.